GlobeNewswire·May 19, 2026, 12:07 PM ET

Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City

Altitude Lab portfolio companies have collectively raised over $205 million in early-stage funding since the program's 2020 launch.
Peel Therapeutics closed a fully subscribed $20 million Series A; its lead asset PEEL-224 showed a 68% disease control rate in Phase 1A trials with limited GI toxicity.
Rebel Medicine raised $7.5 million in Series A funding led by Crocker Ventures & received FDA IND clearance for Alevatrix, now in a Phase 2 opioid-sparing trial.
Leash Bio signed a multi-target agreement with Monte Rosa Therapeutics to accelerate degrader discovery for over 500 difficult-to-drug targets.
Intactis Bio raised $250,000 from Nucleus Fund & demonstrated lab-grown neurons capable of encoding/decoding language & math operations.
Sethera Therapeutics entered negotiations for a CDMRP Breast Cancer Research Program Breakthrough Award & added a Nobel Laureate to its Scientific Advisory Board.
3Helix launched NeoHelix™ Regenerate with BASF, showing a 41% reduction in damaged collagen & a 65% increase in hyaluronic acid in clinical studies.
Calycia Biosciences won Altitude Lab's 2026 Demo Day & secured $400,000 in pre-seed funding from University of Utah Ventures & Cumming Foundation.
Altitude Lab appointed Kapil Sharma as Interim Executive Director to expand national visibility & partnerships.
Chandana Haque stepped down as Executive Director & will continue supporting the organization as a board member.